Phase II trial of esorubicin in advanced pancreatic adenocarcinoma

Cancer Treat Rep. 1986 May;70(5):683-4.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Agranulocytosis / chemically induced
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Doxorubicin / adverse effects
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / therapeutic use
  • Female
  • Heart Diseases / chemically induced
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Doxorubicin
  • esorubicin